Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Cancer drugs from Pfizer and Roche have won recommendations from the National Institute for Health and Care Excellence (NICE), the cost-effectiveness watchdog for England and Wales. 13 May 2020
Biotechnology
Privately-held US biotech Skyhawk Therapeutics has expanded its strategic collaboration with US pharma giant Merck & Co to discover, develop and commercialize small molecules that modulate RNA splicing. 12 May 2020
Biotechnology
Novavx announced late Monday that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate against SARS-CoV-2. 12 May 2020
Biotechnology
California-based neurology specialist Neurocrine Biosciences has exercised its option to license the global rights of Swiss biotech Idorsia's ACT-709478. 12 May 2020
Biotechnology
A trial miss for French metabolic specialist Genfit has sent investors running scared in pre-market trading. 12 May 2020
Biotechnology
CSL Behring, a part of Australia’s CSL Limited, plans to accelerate its expansion in the Russian pharmaceutical market within the next several years, that will take place through the further development of its local portfolio of drugs, according to recent statements by Maria Lituchaya, head of CSL Behring for Russia and the CIS region in an interview with the Russian Kommersant business paper. 12 May 2020
Biotechnology
French drugmaker Sanofi has announced positive data from the Phase III IKEMA trial of Sarclisa (isatuximab) in multiple myeloma. 12 May 2020
Biotechnology
Cambridge, Massachusetts-based biotech Dyno Therapeutics has emerged from stealth with two strategic collaborations to develop improved gene therapies with AAV vectors based on AI (artificial intelligence) technology. 11 May 2020
Biotechnology
Enhertu (fam-trastuzumab deruxtecan-nxki) has been granted a second Breakthrough Therapy designation (BTD) in the USA, this time for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab. 11 May 2020
Biotechnology
The European Medicines Agency’s advisory committee in February, the European Commission has granted a Marketing Authorization for the subcutaneous (SC) formulation of Entyvio (vedolizumab), a gut-selective biologic for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). 11 May 2020
Biotechnology
US biotech firm jCyte Inc has entered into a licensing agreement with Japanese ophthalmology specialist Santen Pharmaceutical to develop and commercialize its first-in-class, investigational therapy, jCell, outside the USA, in regions including Europe, Asia and Japan. 9 May 2020
Biotechnology
The US Food and Drug Administration has granted accelerated approval for Retevmo (selpercatinib) capsules to treat three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers – in patients whose tumors have an alteration (mutation or fusion) in a specific gene (RET or “rearranged during transfection”). 9 May 2020
Biotechnology
Canada-based BetterLife Pharma, previously known as Pivot Pharmaceuticals, has entered into an agreement to acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AntiCovir, a potential COVID-19 treatment, from Canadian biotech Altum Pharmaceuticals. 8 May 2020
Biotechnology
COVID-19 is having varying effects on different markets within healthcare, with drug delivery systems one of those areas that could be given a boost by the pandemic’s impact, according to Fact. MR. 7 May 2020
Biotechnology
Tokyo’s Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) for trastuzumab deruxtecan in Japan. 7 May 2020
Biotechnology
Privately-held Italian pharma group Mediolanum Farmaceutici has acquired the French immuno-oncology specialist ElsaLys Biotech. 7 May 2020
Biotechnology
In another strategic M&A deal announced so far this month, PTC Therapeutics has entered into an agreement to acquire fellow USA-based rare metabolic disease drug developer Censa Pharmaceuticals. 7 May 2020
Biotechnology
Late Wednesday, the US Food and Drug Administration said it has granted accelerated approved for Tabrecta (capmatinib; INC280) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body. 7 May 2020
Biotechnology
A multi-year collaboration between China’s Innovent Biologics and USA-based Eli Lilly is bearing fruit, with positive Phase III data in lung cancer. 7 May 2020
Biotechnology
Mark Brewer, who heads up the life sciences team at UK broker and M&A advisory company, finnCap, gives an overview of some of the growth companies that are currently actively working in the fight against coronavirus in an Expert View piece. 6 May 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze